The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Alnylam Pharmaceuticals, Inc. (NASDAQGS: ALNY) who purchased shares between February 15, 2018 and September 12, 2018. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the Alnylam lawsuit alleges that (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.
Shareholders have until November 26, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >